MFM Ltd: Roger Waters: We are on the road to Frankfurt
28.3.2023 08:51:33 CEST | news aktuell GmbH | Press release
Concert in Frankfurt to be secured by interim injunction
(London, United Kingdom): Roger Waters has noted with pleasure the decision of the Munich City Council that his 21.05.2023 concert in the Olympiahalle Munich will take place as planned:
"I am very happy to be able to perform in Munich for my fans. A ban on my concert would have been illegal. The City of Munich’s decision is good news for freedom of speech in Germany."
Referring to the concert in Frankfurt on 28.05.2023, for which the City of Frankfurt and the State of Hesse are sticking to the cancellation of the contract, Waters went on to say:
"The decision makers in Frankfurt know that they are on the wrong side of the law and are now completely isolated. They should take an example from their colleagues in Munich and instead of wasting a lot of taxpayers’ money on a futile legal action they should follow Munich’s brave example and support freedom in the arts and free speech in general. The cancel attempts of the Frankfurt politicians are an attack on artistic freedom as a whole. Politicians have no right to intimidate and bully artists and their fans with performance bans."
Waters said that he would continue to fight unceasingly for his right to perform in Frankfurt saying:
”I am fighting for all of our human rights, including the right to freedom of speech. We are on the road to Frankfurt. Frankfurt, here we come!”
If pre-court efforts fail, Waters' lawyers will seek to secure the performance of the concert in Frankfurt on 28.05.2023 through an interim injunction. Commenting on this intention, Waters said:
“Like all the other concerts on my European tour, my concert in Frankfurt will take place. I will enforce this in court if I must. So my fans don’t have to worry."
Contacts
HÖCKER Rechtsanwälte PartGmbB
Rechtsanwalt Prof. Dr. Ralf Höcker
Rechtsanwalt Michael Fengler
E-Mail: contact@hoecker.eu
Tel: +49(0)221-93319-10
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Webasto Air Top Pro 25: a new, exceptionally quiet parking heater for campers22.10.2026 13:52:44 CEST | Press release
Why should the camping season end just because summer is over? The colder months offer unique experiences—from skiing and snowshoeing to simply enjoying the winter landscape. To ensure your motorhome or campervan remains a comfortable retreat even in low temperatures, the right heating solution is crucial.
Polarise Launches Sovereign AI Cloud at NVIDIA GTC Berlin, Delivering Enterprise AI From Data Center to Application22.10.2026 10:00:00 CEST | Press release
With Polarise Rise and Polarise Drive, the German AI provider extends its own European AI Factories into a full-stack sovereign cloud
Democracy News Alliance: Fiscal strength doesn't guarantee public goods delivery, US study finds21.10.2026 09:55:20 CEST | Press release
New York/DNA - A newly released study of US state government performance found strong partisan and regional patterns within three pillars of governance: democratic accountability, state capacity and public goods provision. Yet, the US states’ outcomes differ in important ways from international comparisons, as the three governance dimensions show limited correlation, the researchers found.
agineo expands partnership with ServiceNow, launches AI Control Tower as a Service20.10.2026 13:06:01 CEST | Press release
New managed service provides transparency into the AI landscape and helps companies centrally manage AI, monitor risks and regulatory requirements, and highlight business benefits.
Grünenthal advances proprietary Nociceptin Receptor (NOP) Agonist into Phase II trial in acute pain20.10.2026 10:17:49 CEST | Press release
Potential first-in-class, selective nociceptin receptor (NOP) agonist that aims to provide safe, effective treatment for moderate to severe acute pain. Following successful Phase I results earlier this year demonstrating an excellent safety profile, the program has now progressed to Phase II. The randomized, double-blind, double-dummy, placebo- and active controlled, 2-part Phase II trial will evaluate the safety, tolerability and efficacy of this novel NOP agonist in patients post bunionectomy surgery. Grünenthal anticipates reporting results in early 2028.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom